JP2015093833A - 放射性ハロゲン標識化合物又はその塩、これを含む医薬 - Google Patents
放射性ハロゲン標識化合物又はその塩、これを含む医薬 Download PDFInfo
- Publication number
- JP2015093833A JP2015093833A JP2013231954A JP2013231954A JP2015093833A JP 2015093833 A JP2015093833 A JP 2015093833A JP 2013231954 A JP2013231954 A JP 2013231954A JP 2013231954 A JP2013231954 A JP 2013231954A JP 2015093833 A JP2015093833 A JP 2015093833A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- halogen atom
- acid
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 71
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 25
- 229910052736 halogen Inorganic materials 0.000 title claims abstract description 5
- 150000002367 halogens Chemical class 0.000 title claims abstract description 5
- 239000003814 drug Substances 0.000 title claims description 13
- 150000003839 salts Chemical class 0.000 title claims description 13
- 125000005843 halogen group Chemical group 0.000 claims abstract description 25
- 239000012216 imaging agent Substances 0.000 claims abstract description 13
- 238000002059 diagnostic imaging Methods 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 7
- 238000003325 tomography Methods 0.000 claims description 5
- 208000020576 Adrenal disease Diseases 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 abstract description 20
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 abstract description 17
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 abstract description 13
- 238000009825 accumulation Methods 0.000 abstract description 10
- 210000004100 adrenal gland Anatomy 0.000 abstract description 10
- 210000000056 organ Anatomy 0.000 abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- -1 4- (5-Iodo-1H-imidazol-1-ylmethyl) benzonitrile Chemical compound 0.000 description 25
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 18
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 17
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 17
- 229960002478 aldosterone Drugs 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 230000001919 adrenal effect Effects 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000016998 Conn syndrome Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 6
- 229960001690 etomidate Drugs 0.000 description 6
- 208000013846 primary aldosteronism Diseases 0.000 description 6
- FHFZEKYDSVTYLL-UHFFFAOYSA-N Methomidate Chemical compound COC(=O)C1=CN=CN1C(C)C1=CC=CC=C1 FHFZEKYDSVTYLL-UHFFFAOYSA-N 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960002047 metomidate Drugs 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 125000002130 sulfonic acid ester group Chemical group 0.000 description 5
- FKWSYPOMKWYQFX-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C2=CC=CC=C2)OCCCC3=CN(C=N3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C2=CC=CC=C2)OCCCC3=CN(C=N3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6 FKWSYPOMKWYQFX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- QJHZPCLORSPENH-YVJYXHLXSA-N (3s,6r,8s,9s,13r,14s,17r)-6-(iodomethyl)-13-methyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C1([C@H](CI)C[C@H]2[C@@H]3CC[C@@H]([C@]3(CC[C@@H]22)C)[C@H](C)CCCC(C)C)=C2CC[C@H](O)C1 QJHZPCLORSPENH-YVJYXHLXSA-N 0.000 description 3
- JEVPOYFZJLLZIA-UHFFFAOYSA-N 3-(1-tritylimidazol-4-yl)propan-1-ol Chemical compound C1=NC(CCCO)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 JEVPOYFZJLLZIA-UHFFFAOYSA-N 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000761960 Homo sapiens Cytochrome P450 11B1, mitochondrial Proteins 0.000 description 3
- 101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 206010001323 adrenal adenoma Diseases 0.000 description 3
- 208000015234 adrenal cortex adenoma Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical group CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- KKKDZZRICRFGSD-UHFFFAOYSA-N 1-benzylimidazole Chemical class C1=CN=CN1CC1=CC=CC=C1 KKKDZZRICRFGSD-UHFFFAOYSA-N 0.000 description 2
- ARVPJXNDEPHFGE-UHFFFAOYSA-N 3-[3-[(4-iodophenyl)methyl]imidazol-4-yl]propan-1-ol Chemical compound OCCCC1=CN=CN1CC1=CC=C(I)C=C1 ARVPJXNDEPHFGE-UHFFFAOYSA-N 0.000 description 2
- 125000006483 4-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1I)C([H])([H])* 0.000 description 2
- BHCMXJKPZOPRNN-UHFFFAOYSA-N 5-iodo-1h-imidazole Chemical compound IC1=CN=CN1 BHCMXJKPZOPRNN-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 2
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 2
- LYRCQNDYYRPFMF-UHFFFAOYSA-N trimethyltin Chemical group C[Sn](C)C LYRCQNDYYRPFMF-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- PBKHCKQTQXHKLE-UHFFFAOYSA-N (4-iodophenyl)methanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=C(I)C=C1 PBKHCKQTQXHKLE-UHFFFAOYSA-N 0.000 description 1
- 0 *c1cnc[n]1Cc1ccc(*)cc1 Chemical compound *c1cnc[n]1Cc1ccc(*)cc1 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BQTRMYJYYNQQGK-UHFFFAOYSA-N 1-(bromomethyl)-4-iodobenzene Chemical compound BrCC1=CC=C(I)C=C1 BQTRMYJYYNQQGK-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
- OFGDSGVGRWPQJQ-UHFFFAOYSA-N 1h-imidazol-1-ium;acetate Chemical compound CC(O)=O.C1=CNC=N1 OFGDSGVGRWPQJQ-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- DXJZJYPLPZEYBH-UHFFFAOYSA-N 4-iodo-1-tritylimidazole Chemical compound C1=NC(I)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 DXJZJYPLPZEYBH-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- ULZWPDQVRBLWNJ-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C2=CC=CC=C2)OCCCC3=CN=CN3CC4=CC=C(C=C4)I Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C2=CC=CC=C2)OCCCC3=CN=CN3CC4=CC=C(C=C4)I ULZWPDQVRBLWNJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- ZMXDDKWLCZADIW-YYWVXINBSA-N DMF-d7 Substances [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101100219201 Homo sapiens CYP11B1 gene Proteins 0.000 description 1
- 101100219207 Homo sapiens CYP11B2 gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
- STLNVFIYTAAFOW-UHFFFAOYSA-L [OH-].[Na+].[I-].[Na+] Chemical compound [OH-].[Na+].[I-].[Na+] STLNVFIYTAAFOW-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
・放射性ヨウ素標識5−ヨード−1−ニトロベンジル−1H−イミダゾ−ル(化合物Aにおいて、R1が放射性ヨウ素原子の化合物)
・放射性ヨウ素標識4−(5−ヨード−1H−イミダゾ−ル−1−イルメチル)ベンゾニトリル(化合物Bにおいて、R1が放射性ヨウ素原子の化合物)
・放射性ヨウ素標識3−[1−(4−ヨ−ドベンジル)−1H−イミダゾ−ル−5−イル]プロパン−1−オ−ル(化合物Cにおいて、R1がヒドロキシプロピル基であり、R2が放射性ヨウ素原子の化合物)
がより好ましい。
CDP1260:4−(5−ヨード−1H−イミダゾ−ル−1−イルメチル)ベンゾニトリル
CDP1450:3−[1−(4−ヨ−ドベンジル)−1H−イミダゾ−ル−5−イル]プロパン−1−オ−ル
CDP1980:5−ヨード−1−ニトロベンジル−1H−イミダゾ−ル
[123I]CDP1260:4−(5−[123I]ヨード−1H−イミダゾ−ル−1−イルメチル)ベンゾニトリル
CDP1260(化合物3)は、図1に示すスキームに従って合成した。
4−ヨード−1H−イミダゾール(化合物1)(1.9g,10mmol)をジクロロメタン(40mL)に溶解したのち、氷冷下、トリエチルアミン(2.1mL,15mmol)、塩化トリチル(3.4g,12mmol)を加え、アルゴンガス雰囲気下、室温(25℃)で17時間攪拌した。反応終了後、水を加え、ジクロロメタンで2回抽出を行った。合わせたジクロロメタン層を無水硫酸ナトリウムで乾燥後減圧濃縮し、得られた粗生成物をシリカゲルカラムクロマトグラフィー(溶離液:クロロホルム/n−ヘキサン=1/1→クロロホルム)にて精製を行い、化合物2(4.1g,9.3mmol,収率93%)を得た。
使用NMR装置:AVANCEIII
1H−NMR(重クロロホルム):δ 7.36−7.34(m,9H),7.31(d,J=1.5Hz,1H),7.13−7.11(m,6H),6.80(d,J=1.5Hz,1H)。
ステップ1−1で得た化合物2(2.2g,5.0mmol)をアセトニトリル(16mL)、クロロホルム(4.0mL)に溶解したのち、室温(25℃)にて4−シアノベンジルブロミド(980mg,5.0mmol)を加え、アルゴンガス雰囲気下、80℃で一晩撹拌した。反応終了後、反応溶液を減圧濃縮し、酢酸(7.5mL)、水(5.0mL)を加え、100℃で4時間撹拌した。反応終了後、飽和炭酸水素ナトリウム水溶液を加えてpHを9としたのち、ろ過を行った。ろ液をクロロホルムで2回抽出を行ったのち、合わせたクロロホルム層を無水硫酸ナトリウムで乾燥後減圧濃縮し、得られた粗生成物をシリカゲルクロマトグラフィー(溶離液:ジクロロメタン/酢酸エチル=4/1)にて精製を行い、CDP1260(790mg,2.6mmol,収率51%)を得た。
使用NMR装置:AVANCEIII
1H−NMR(重クロロホルム):δ 7.72(s,1H),7.67−7.65(m,2H),7.22(s,1H),7.18−7.16(m,2H),5.21(s,2H)。
[123I]CDP1260の標識前駆体である4−(5−トリブチルスタニル−1H−イミダゾ−ル−1−イルメチル)ベンゾニトリル(化合物4)は、図1に示すスキームに従って合成した。
実施例1で得たCDP1260(30mg,0.10mmol)をジメチルホルムアミド(1mL)に溶解したのち、ビストリブチルスズ(100μL,0.20mmol)、ビス(トリ−tert−ブチルホスフィン)パラジウム(10.2mg,0.020mmol)を加え、アルゴンガス雰囲気下、100℃にて一晩撹拌した。反応終了後、反応溶液を冷却し、酢酸エチルで抽出を行った。有機層を無水硫酸ナトリウムで乾燥後減圧濃縮し、得られた粗生成物をシリカゲルカラムクロマトグラフィー(溶離液:ジクロロメタン/メタノール=20/1)にて精製を行い、化合物4(9.8mg,0.021mmol,収率21%)を得た。
使用NMR装置:AVANCEIII
1H−NMR(重クロロホルム,共鳴周波数:500MHz):δ 7.74(s,1H),7.62(d,J=8.5Hz,2H),7.13(s,1H),7.04(d,J=8.5Hz,2H),5.22(s,2H),1.41−1.34(m,6H),1.27−1.20(m,6H),0.88−0.83(m,15H)。
実施例2で合成した化合物4のアセトニトリル溶液(1mg/mL,90μL)に、1mol/L塩酸(170μL)、[123I]ヨウ化ナトリウムの水酸化ナトリウム水溶液(620MBqの60μL)及び30%(w/v)過酸化水素水溶液(10μL)を添加した。当該混合液を40℃にて10分間静置した後、下記の条件のHPLCに付して、実施例1で得たCDP1260と保持時間が同じ画分を[123I]CDP1260画分として分取した。
<HPLC条件>
カラム:YMC PackPro C8(YMC社製、サイズ:4.5×150mm)
移動相:0.1%トリフルオロ酢酸含む水/0.1%トリフルオロ酢酸含むアセトニトリル(体積比)=90/10から10/90へ40分かけてグラジエント
流速:1.0mL/分
検出器:紫外可視吸光光度計(検出波長:260nm)及び放射線検出器(raytest社 STEFFI型)
<TLC分析条件>
TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:酢酸エチル/ジエチルアミン=100:5
RI検出器:Rita Star、raytest社製
CDP1450(化合物11)は、図2に示すスキームに従って合成した。
ウロカニン酸(化合物5)(5g,36.2mmol)をメタノ−ル(400mL)に溶解したのち、パラジウム−炭素(3g)を加え、水素ガス雰囲気下、室温(25℃)で一晩撹拌した。反応終了後、反応溶液をろ過したのち、ろ液を減圧濃縮した。得られた粗生成物をエタノ−ル(400mL)に溶解したのち、濃硫酸(20.0mL)を加え、アルゴンガス雰囲気下、一晩加熱還流した。反応終了後、反応溶液を冷却し、4mol/L水酸化ナトリウム水溶液を加えて中和したのち、ジクロロメタンで抽出した。有機層を無水硫酸ナトリウムで乾燥後減圧濃縮し、化合物6(5g,29.7mmol,化合物5に対する2段階収率82%)を得た。
使用NMR装置:JNM−ECP−500
1H−NMR(重クロロホルム):δ 7.55(s,1H),6.81(s,1H),4.14(t,J=7.4Hz,2H),2.92(t,J=6.9Hz,2H),2.65(t,J=6.9Hz,2H),1.24(t,J=7.4Hz,3H)。
ステップ4−1で得た化合物6(5g,29.7mmol)をジクロロメタン(150mL)に溶解したのち、塩化トリチル(12.4g,44.6mmol)、トリエチルアミン(8.28mL,59.4mmol)を加え、アルゴンガス雰囲気下、室温(25℃)で一晩撹拌した。反応終了後、飽和炭酸水素ナトリウム水溶液を加え、ジクロロメタンで抽出を行った。有機層を無水硫酸ナトリウムで乾燥後減圧濃縮し、得られた粗生成物をシリカゲルカラムクロマトグラフィー(溶離液:ジクロロメタン/酢酸エチル=10/1→5/1)にて精製を行い、化合物7(10g,24.4mmol,収率83%)を得た。
使用NMR装置:JNM−ECP−500
1H−NMR(重クロロホルム):δ 7.33−7.30(m,10H),7.13−7.11(m,6H),6.54(s,1H),4.09−4.05(m,2H),2.88−2.85(m,2H),2.62(t,J=7.4Hz,2H),1.20−1.17(m,3H)。
ステップ4−2で得た化合物7(10g,24.4mmol)をテトラヒドロフラン(120mL)に溶解したのち、水素化リチウムアルミニウム(1.44g,38.0mmol)を加え、アルゴンガス雰囲気下、室温(25℃)で一晩撹拌した。反応終了後、無水硫酸ナトリウムと水を加え、反応溶液をろ過したのち、ろ液を減圧濃縮し、化合物8(9.67g,26.2mmol,定量)を得た。
使用NMR装置:JNM−ECP−500
1H−NMR(重ジメチルスルホキシド):δ 7.42−7.36(m,10H),7.08(d,J=6.9Hz,6H),6.57(s,1H),4.41−4.39(m,1H),3.39−3.36(m,2H),2.46−2.43(m,2H),1.68−1.63(m,2H)。
ステップ4−3で得た化合物8(9.67g,26.2mmol)をジクロロメタン(100mL)に溶解したのち、tert−ブチルジフェニルクロロシラン(13.4mL,52.4mmol)、トリエチルアミン(7.3mL,52.4mmol)を加え、アルゴンガス雰囲気下、室温(25℃)で一晩撹拌した。反応終了後、飽和炭酸水素ナトリウム水溶液を加え、ジクロロメタンで抽出を行った。有機層を無水硫酸ナトリウムで乾燥後減圧濃縮し、得られた粗生成物をシリカゲルカラムクロマトグラフィー(溶離液:ジクロロメタン/酢酸エチル=20/1)にて精製を行い、化合物9(15.1g,24.8mmol,収率95%)を得た。
使用NMR装置:JNM−ECP−500
1H−NMR(重クロロホルム):δ 7.64−7.62(m,4H),7.39−7.25(m,16H),7.12−7.10(m,6H),6.48(s,1H),3.69−3.66(m,2H),2.66−2.63(m,2H),1.92−1.86(m,2H),1.01(s,9H)。
ステップ4−4で得た化合物9(2.0g,3.3mmol)をアセトニトリル(6.0mL)に溶解したのち、4−ヨードベンジルブロミド(1.0g,3.5mmol)を加え、アルゴンガス雰囲気下、2時間半加熱還流した。反応終了後、反応溶液を減圧濃縮し、メタノ−ル(5.7mL)に溶解したのち、ジエチルアミン(0.3mL)を加え、アルゴンガス雰囲気下、3時間加熱還流した。反応終了後、反応溶液を冷却し、減圧濃縮して得られた粗生成物をシリカゲルカラムクロマトグラフィー(溶離液:酢酸エチル→酢酸エチル/メタノール=20/1→10/1)にて精製を行い、化合物10(1.0g,1.8mmol,収率56%)を得た。
使用NMR装置:AVANCEIII
1H−NMR(重クロロホルム):δ 7.65−7.59(m,6H),7.46−7.41(m,3H),7.37−7.34(m,4H),6.80(s,1H),6.72(d,J=8.3Hz,1H),4.97(s,2H),3.67(t,J=6.0Hz,2H),2.50−2.47(m,2H),1.80−1.75(m,2H),1.01(s,9H)。
ステップ4−5で得た化合物10(1.0g,1.8mmol)をテトラヒドロフラン(2mL)に溶解したのち、テトラブチルアンモニウムフルオリド(1.0mmol)のテトラヒドロフラン溶液(2.16mL)を加え、アルゴンガス雰囲気下、室温(25℃)で一晩撹拌した.反応終了後、反応溶液を濃縮し、シリカゲルカラムクロマトグラフィー(溶離液:酢酸エチル/メタノ−ル=19/1→9/1→17/3)にて精製を行い、CDP1450(0.54g,0.42mmol,収率95%)を得た。
使用NMR装置:AVANCEIII
1H−NMR(重クロロホルム):δ 7.67−7.65(m,2H),7.46(s,1H),6.86(s,1H),6.78−6.77(m,2H),5.02(s,2H),3.67−3.65(m,2H),2.52−2.49(m,2H),1.86−1.79(m,2H)。
CDP1980(化合物12)は、図3に示すスキームに従って合成した。
使用NMR装置:AVANCEIII
1H−NMR(重クロロホルム):δ 8.22(d,J=8.8Hz,2H),7.74(s,1H),7.24−7.22(m,3H),5.26(s,2H)。
チャイニーズハムスター肺由来線維芽細胞であるV79細胞(DSファーマバイオメディカル株式会社を介しECACC(European Collection of Cell Cultures)から入手)にヒトCYP11B2を発現させV79−B2を、またヒトCYP11B1を発現させ、V79−B1を作製した。V79−B2又はV79−B1をマイクロプレートに播種し、一晩培養した後、V79−B2にはコルチコステロン,V79−B1には11−デオキシコルチゾールを最終濃度が100nmol/Lになるように培養上清中に添加した。同時に、最終濃度が10−4〜103nmol/Lになるように培養上清中に、(R)−4−ヨードメトミデート((R)−IMTO)、又は、実施例1、4、5で合成したCDP1260、1450、1980をそれぞれ添加した。1時間後にV79−B1の培養上清を回収し、CYP11B1の代謝産物であるコルチゾール濃度をELISA(Enzyme−Linked ImmunoSorbent Assay)により測定した。また、4時間後にV79−B2の培養上清を回収し、CYP11B2の代謝産物であるアルドステロン濃度をELISAにより測定した。(R)−IMTO、又は、CDP1260、1450、1980を添加しなかった場合のアルドステロン濃度、及び、コルチゾール濃度を100%として、阻害曲線を作成し,各化合物の阻害活性(IC50)を算出した。
実施例3で得た[123I]CDP1260のHPLC分取液を濃縮し生理食塩水で希釈したものを投与液とした。約3.7MBq,約40μLを2〜3匹のラット(雄,8〜9週齢)へそれぞれ尾静脈注射した後、10分後に断頭し、血液を採取した後、臓器(心臓、肺、胃、肝臓、脾臓、小腸、大腸、腎臓、膀胱(尿を含む)、下肢の筋肉、全脳、副腎、甲状腺、精巣、脂肪、その他の組織及び臓器(残全身))を摘出して、重量を計量後、血液及び各摘出臓器の放射能を測定した。また、断頭の時間点を30分後及び60分後に変えて同様な操作を行った。表3には、血液及び各摘出臓器における放射能分布(%dose/g)の平均値±標準偏差を示す。
Claims (7)
- 前記放射性ハロゲン原子が、放射性ヨウ素原子である、請求項1に記載の放射性ハロゲン標識化合物又はその塩。
- 請求項1又は2に記載の放射性ハロゲン標識化合物又はその塩を含む医薬。
- 画像診断剤である請求項3記載の医薬。
- 副腎疾患の画像診断剤である請求項3又は4記載の医薬。
- シングルフォトン断層撮影用の画像診断剤である請求項3乃至5いずれか一項に記載の医薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013231954A JP2015093833A (ja) | 2013-11-08 | 2013-11-08 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013231954A JP2015093833A (ja) | 2013-11-08 | 2013-11-08 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015093833A true JP2015093833A (ja) | 2015-05-18 |
Family
ID=53196483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013231954A Pending JP2015093833A (ja) | 2013-11-08 | 2013-11-08 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2015093833A (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190016971A (ko) | 2016-06-10 | 2019-02-19 | 니혼 메디피직스 가부시키가이샤 | 심질환의 비침습적 화상 진단제 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050033060A1 (en) * | 2003-08-06 | 2005-02-10 | Ilse Zolle | Radiolabelled phenylethyl imidazole caboxylic acid ester derivatives |
WO2009106640A2 (en) * | 2008-02-28 | 2009-09-03 | Maastricht University | N-benzyl imidazole derivatives |
-
2013
- 2013-11-08 JP JP2013231954A patent/JP2015093833A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050033060A1 (en) * | 2003-08-06 | 2005-02-10 | Ilse Zolle | Radiolabelled phenylethyl imidazole caboxylic acid ester derivatives |
WO2009106640A2 (en) * | 2008-02-28 | 2009-09-03 | Maastricht University | N-benzyl imidazole derivatives |
Non-Patent Citations (3)
Title |
---|
ROUMEN, L. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol. 53, JPN6017026115, 2010, pages pp. 1712-1725 * |
SCHIRBEL, A. ET AL.: "[123/131I]iodometomidate as a radioligand for functional diagnosis of adrenal disease: Synthesis, st", RADIOCHIMICA ACTA, vol. Vol. 92, No. 4-6, JPN6016018542, 2004, pages pp. 297-303 * |
尾川 浩一, 核データニュース, vol. No. 70, JPN7017002280, 2001, pages pp. 28-37 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190016971A (ko) | 2016-06-10 | 2019-02-19 | 니혼 메디피직스 가부시키가이샤 | 심질환의 비침습적 화상 진단제 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6636921B2 (ja) | 2−(3−ピリジニル)−1h−ベンゾイミダゾール誘導体化合物、及び、これを含む医薬 | |
US8071785B2 (en) | Synthesis and evaluation of 18F-labelled-alkyl-1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate as a tracer for the quantification of β-11-hydroxylase enzyme in the adrenal glands | |
JP6048958B2 (ja) | 副腎疾患の画像診断剤 | |
US11266753B2 (en) | 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same | |
CA2384879C (en) | Nitroimidazole derivative and diagnostic imaging agent containing the same | |
JP2015093833A (ja) | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 | |
JP2015110563A (ja) | アルドステロン合成酵素阻害剤 | |
JP2015093832A (ja) | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 | |
CN112638868B (zh) | 由正电子放射性核素标记的脂肪酸衍生物 | |
US9814789B2 (en) | Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma | |
JP2015093831A (ja) | アルドステロン合成酵素阻害剤 | |
JP2015193545A (ja) | 2−(3−ピリジニル)−1h−ベンズイミダゾール誘導体化合物、これを含む放射性医薬 | |
CN114945557B (zh) | 由正电子放射性核素标记的脂肪酸衍生物 | |
JP2014122177A (ja) | 放射性ヨード標識前駆体の製造方法 | |
TW201210621A (en) | Fluorodeuteriomethyl tyrosine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170718 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170713 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20170721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170724 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180228 |